natgillin/translations-raw huggingface dataset:
Nivolumab in combination with ipilimumab
Nivolumab v kombinaciji z ipilimumabom
Nivolumab in combination with ipilimumab should be discontinued for life-threatening or recurrent severe cardiac and pulmonary adverse reactions.
V primeru pojava življenje ogrožajočih ali ponovitve hudih neželenih učinkov za srce in pljuča je treba zdravljenje z nivolumabom v kombinaciji z ipilimumabom ukiniti.
Nivolumab is associated with immune-related adverse reactions.
Uporaba nivolumaba je povezana s pojavom imunsko pogojenih neželenih učinkov.
Nivolumab is unlikely to affect your ability to drive or use machines; however, use caution when performing these activities until you are sure that nivolumab does not adversely affect you.
Verjetnost vpliva nivolumaba na sposobnost upravljanja vozil in strojev je majhna, vendar pa morate biti vseeno pozorni, da nivolumab pri vas nima negativnih vplivov na tovrstne aktivnosti.
Nivolumab must be permanently discontinued for any severe immune-related adverse reaction that recurs and for any life-threatening immune-related adverse reaction.
Če se kateri koli resni imunsko pogojeni neželeni učinek ponovi, ali pojavi kateri koli resni imunsko pogojeni neželeni učinek, ki ogrozi življenje, je treba zdravljenje z nivolumabom trajno ukiniti.
Nivolumab+ipilimumab vs nivolumab (descriptive analysis) - HR (95% CI): 0.76 (0.62, 0.95)
< 0,0001 nivolumab+ipilimumab v primerjavi z nivolumabom (opisna analiza) - HR (95 % IZ): 0,76 (0,62; 0,95)
Nizatidine Ranitidine
cimetidin nizatidin ranitidin
NK cells are known to express high levels of CD38 and are susceptible to daratumumab mediated cell lysis.
Znano je, da celice NK izražajo velike količine proteina CD38 in so dovzetne z daratumumabom posredovano citolizo.
NL-1186 DM Amstelveen Tel: +31 20 751 65 00
Tel: +356 21 446 205
NL-1411DD Naarden The Netherlands
NL-1411 DD Naarden Nizozemska
NL-4817 ZK Breda
Dompé Biotec S.p.A.
NL-5612 AZ, Eindhoven The Netherlands
NL-5612 Az, Eindhoven Nizozemska
NMBA and dose to be administered
Mišični relaksant in odmerek, ki ga je potrebno uporabiti
NMS (Neuroleptic Malignant Syndrome):
MNS (maligni nevroleptični sindrom)
NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products.
MNS je potencialno usoden skupek simptomov, povezan z antipsihotičnimi zdravili.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal product.
NMS je potencialno življenje ogrožajoče stanje, povezano z antipsihotiki.
NN:
Izločanje
NN:>
2019
NNRTI 78 %
374 (345, 403)
NNRTI-based
na osnovi NNRTI
NNRTIs other than rilpivirine (efavirenz, etravirine, and nevirapine) are contraindicated (see section 4.3).
Drugi NNRTI razen rilpivirina (efavirenz, etravirin in nevirapin) so kontraindicirani (glejte poglavje 4.3).
NNRTIs: careful monitoring for any occurrence of drug toxicity and/or lack of anti-viral efficacy, and dose adjustment if required.
NNRTI: skrbno spremljati vsakršen pojav toksičnih učinkov zdravila in/ali pomanjkanja učinkovitosti protivirusnega delovanja ter prilagoditi odmerek, če je to potrebno.
no
enou
no
os os
No (for any parameter listed above)
Ne (za kateri koli zgoraj našteti parameter)
No a-priori dose adjustment is required on the basis of a patient’s age.
Začetnega odmerka ni treba v naprej prilagoditi samo zaradi bolnikove starosti.
No accumulation for Cmax was observed.
Akumulacije za Cmax niso opazili.
No accumulation occurs after multiple-dose administration.
Po uporabi večkratnih odmerkov ni kopičenja.
No accumulation occurs during chronic administration.
Med dolgoročno uporabo zdravila ne prihaja do njegovega kopičenja.
No accumulation of dalbavancin was observed following multiple intravenous infusions administered once-weekly for up to 8 weeks (1000 mg on Day 1, followed by up to 7 weekly 500 mg doses) in healthy adults.
Kopičenja dalbavancina po večkratnem intravenskem infundiranju enkrat tedensko v obdobju do 8 tednov (1000 mg prvi dan, potem pa še do 7 tedenskih odmerkov po 500 mg) pri zdravih odraslih osebah, niso opazili.
No accumulation of elosulfase alfa in plasma was evident following weekly dosing.
Po odmerjanju enkrat tedensko ni bilo opaziti kopičenja elosulfaze alfa v plazmi.
No accumulation of palifermin occurred after 3 consecutive daily doses
Po 3 zaporednih dnevnih odmerkih 20 in 40 mikrogramov/kg (zdravi prostovoljci) oz.
No accumulation of teduglutide was observed following repeated subcutaneous administration.
Ob ponovljenem vnosu v podkožje niso zabeležili akumulacije teduglutida.
No accumulation of teduglutide was observed following repeated subcutaneous administrations.
Ob ponovljenih vnosih v podkožje niso zabeležili akumulacije teduglutida.
No action needs to be taken if this is observed.
Ukrepati ni potrebno.
No additional adverse reactions have been identified for the combination of alendronate and colecalciferol.
Pri kombinaciji alendronata in holekalciferola niso ugotovili dodatnih neželenih učinkov.
No additional chlorine, for example from the use of water chlorinators, or hydrogen peroxide should be added to the drinking water used with this product.
Vodi, kateri je primešano zdravilo, ne dodajajte klorovih pripravkov (za kloriranje vode) ali vodikovega peroksida.
No additional dose adjustments are recommended for older people.
Pri starejših ljudeh ni potrebno dodatno prilagajanje odmerjanja.
No additional food should be consumed for up to 2 hours after administration of efavirenz.
Do 2 uri po zaužitju zdravila efavirenz se ne sme uživati dodatne hrane.
No additional food should be consumed for up to 2 hours after administration of efavirenz..
Po uporabi efavirenza hrane ne uživajte še nadaljnji 2 uri.
No additional studies were needed as Bortezomib Accord is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Velcade.
Ker je zdravilo Bortezomib Accord generično zdravilo, ki se daje z injiciranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Velcade, niso bile potrebne nobene dodatne študije.
No additional studies were needed as Nordimet is a hybrid medicine that is given by injection and contains the same active substance as the reference medicine, Lantarel FS.
Ker je zdravilo Nordimet hibridno zdravilo, ki se daje z injekcijo in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Lantarel FS, niso bile potrebne nobene dodatne študije.
No additional studies were needed as Sevohale is a generic medicine that is given by inhalation and contains the same active substance as the reference medicine, SevoFlo.
Ker je zdravilo Sevohale generično zdravilo, ki se daje z inhaliranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo SevoFlo, niso bile potrebne nobene dodatne študije.
No additional studies were needed as Voriconazole Hospira is a generic medicine that is given by infusion and contains the same active substance as the reference medicine Vfend.
Ker je zdravilo Voriconazole Hospira generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Vfend, niso bile potrebne nobene dodatne študije.
No additional studies were needed as Zoledronic Acid Accord is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.
Ker je zdravilo Zoledronic Acid Accord generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Zometa, niso bile potrebne nobene dodatne študije.
No adequate and well-controlled studies of Kalydeco in pregnant women have been conducted.
Primernih in dobro kontroliranih študij zdravila Kalydeco pri nosečnicah niso izvedli.
No adequate clinical data on exposed pregnancies are available for amifampridine.
Kliničnih podatkov o uporabi amifampridina pri nosečnicah ni.
No ADHD
Brez ADHD
No adjustment
brez prilagoditve
No adjustment in starting dose is required for elderly patients.
Starejšim bolnicam začetnega odmerka ni treba prilagoditi.
No adjustment of digoxin dose is required based on these results.
Prilagoditev odmerka digoksina na podlagi teh rezultatov ni potrebna.
No adjustment of methadone dose is required
potrebna prilagoditev odmerka metadona.
No adjustment of starting dose is required on the basis of hepatic function in patients with mild (Child- Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Prilagoditev začetnega odmerka na podlagi jetrne funkcije pri bolnikih z blago (Child-Pugh A) ali zmerno (Child-Pugh B) okvaro jeter ni potrebna.
No adjustment of the buprenorphine dose is
Pri sočasni uporabi s telaprevirjem ni potrebno
No adjustment of the initial dosage of Rasilez is required in patients with mild to moderate renal impairment (see sections 4.2 and 4.4).
Pri bolnikih z blago do zmerno okvaro ledvic ni treba prilagajati začetnega odmerjanja zdravila Rasilez (glejte poglavji 4.2 in 4.4).
No adjustment of the initial dose is required for elderly patients.
Starejšim bolnikom ni potrebno prilagajati začetnega odmerka.
No adjustment of the initial dose is required for patients with mild to severe hepatic impairment (see section 5.2).
Bolnikom z blago do hudo okvaro jeter ni potrebno prilagajati začetnega odmerka (glejte poglavje 5.2).
No adjustment of the initial dose is required in patients >65 years of age.
Bolnikom, starejšim od 65 let, začetnega odmerka ni treba prilagoditi.
No adjustment of the initial dosing is required on the basis of a patient’s age (see section 5.2).
Začetnega odmerka ni treba prilagajati bolnikovi starosti (glejte poglavje 5.2).
No adjustment of the recommended dose of telbivudine is necessary in patients whose creatinine clearance is  50 ml/min.
Pri bolnikih z očistkom kreatinina ≥50 ml/min ni potrebno prilagajati priporočenega odmerka telbivudina.
No adjustment of the standard dose is recommended in patients with mild renal impairment (see section 5.2).
Pri bolnikih z blago ledvično okvaro se ne priporočajo nobene spremembe standardnega odmerka (glejte poglavje 5.2).
No adjustment of the starting dose is needed for patients with mild hepatic impairment (Child Pugh A) based on clinical data.
Začetnega odmerka pri bolnikih z blago jetrno okvaro na podlagi kliničnih podatkov ni treba prilagajati (Child Pugh A; glejte poglavje 4.4).
No adjustment of the starting dose is recommended in patients with mild hepatic impairment.
Pri bolnikih z blago jetrno okvaro ni priporočil glede prilagajanja začetnega odmerka.
No adjustment of the starting dose is recommended in patients with mild or moderate renal impairment (see sections 4.4 and 5.2).
Pri bolnikih z blago ali zmerno ledvično okvaro ni priporočil glede začetnega odmerka (glejte poglavji 4.4 in 5.2).
No adjustment of the starting dose is required on the basis of patient’s race (see sections 5.1 and 5.2).
Začetnega odmerka ni treba prilagajati glede na etnično skupino (glejte poglavji 5.1 in 5.2).
No adjustment of the starting dose of pomalidomide is required for patients with hepatic impairment as defined by the Child- Pugh criteria.
Pri bolnikih z okvaro jeter, opredeljeno po Child-Pughovih kriterijih, ni potrebna prilagoditev začetnega odmerka pomalidomida.
No adjustment to the dose regimen is needed in patients with mild or moderate renal impairment.
Pri bolnikih z blago ali zmerno okvaro ledvic režima odmerjanja ni treba prilagajati.
No adjustment was made for multiple testing.
Pri večkratnem testiranju ni bila opravljena prilagoditev.
No adverse effects of memantine were noted on fertility in rats and rabbits (see section 5.3).
Pri podganah in kuncih niso opazili neželenih učinkov memantina na plodnost (glejte poglavje 5.3).
No adverse effects on fertility or general reproductive performance were noted in rats given IV Rienso at doses up to 18 mg Fe/kg/day (Human Equivalent Dose of 2.9 mg Fe/kg/day).
Pri i.v. dajanju zdravila Rienso podganam v odmerkih do 18 mg Fe/kg/dan (kar ustreza odmerku 2,9 mg Fe/kg/dan pri človeku), niso opazili neželenih učinkov na plodnost ali splošno sposobnost razmnoževanja.
No adverse effects on fertility were observed in male and female rats administered lomitapide at systemic exposures (AUC) estimated to be 4 to 5 times higher than in humans at the maximum recommended human dose (see section 5.3).
Pri samcih in samicah podgan, ki so prejemale lomitapid v obliki sistemske izpostavitve (AUC), za katero so ocenili, da je 4- do 5-krat večja kot največji priporočeni odmerek za človeka (glejte poglavje 5.3), niso opazili nobenih neželenih učinkov na plodnost.
No adverse effects were observed after a 10-fold overdose.
Po 10-kratnem prekoračenem odmerku zdravila ni bilo opaziti nobenih neželenih učinkov.
No adverse effects were observed in a fertility study in female rats at doses up to 22 times the maximum recommended human dose on a mg/m2 basis.
V študiji plodnosti na samicah podgan pri odmerkih, do 22-krat večjih od največjega priporočenega odmerka za človeka v mg/m2, niso ugotovili neželenih učinkov.
No adverse effects were observed in cats aged 8 weeks and older treated 7 times at two-week intervals with 3-5 times the recommended dose.
Pri mačkah, starih 8 tednov ali več, zdravljenih 7-krat v dvotedenskih intervalih s 3 – 5-kratnim priporočenim odmerkom ni bilo opaziti neželenih učinkov.
No adverse effects were observed in dogs and cats aged 8 weeks or older when administered 5 times the recommended dose on 8 occasions at 4 weeks intervals or administered 5 times the recommended dose on 6 occasions at 2 weeks intervals.
Nobenih neželenih učinkov niso opazili pri psih in mačkah, starih 8 tednov ali več, ko so jim dali 5- kratni priporočeni odmerek 8-krat v 4-tedenskih razmakih ali 5-kratni priporočeni odmerek 6-krat v 2- tedenskih razmikih.
No adverse effects were observed in healthy dogs and puppies aged 8 weeks and older treated 7 times at two-week intervals with 3-5 times the recommended dose.
Pri zdravih psih in mladičkih, starih 8 tednov ali več, zdravljenih 7-krat v dvotedenskih intervalih s 3 – 5-kratnim priporočenim odmerkom ni bilo opaziti neželenih učinkov.
No adverse effects were observed in sexually mature female cynomolgus monkeys exposed to pertuzumab.
Pri spolno zrelih samicah opic cynomolgus, ki so bile izpostavljene pertuzumabu, niso ugotovili neželenih učinkov.
No adverse effects were seen in rats given a single dose of 1000 μg/kg or in monkeys after repeated administration of romiplostim at 500 µg/kg (100 or 50 times the maximum clinical dose of 10 µg/kg, respectively).
Pri podganah, ki so dobile posamičen odmerek 1.000 µg/kg, in opicah po večkratni uporabi 500 µg/kg romiplostima (prvo je 100-kratni, drugo pa 50-kratni največji klinični odmerek 10 µg/kg) niso ugotovili neželenih učinkov.
No adverse effects were seen on maternal well-being or female fertility, embryo-foetal and peri- and post-natal reproductive indices in rats using a rodent anti-rat TNFα PEGylated Fab' (cTN3 PF) following sustained TNFα suppression.
Pri podganah pri uporabi glodalčjega pegiliranega Fab' proti podganjemu TNF-α (cTN3 PF) in podaljšanem zaviranju TNF-α niso opazili nobenih neželenih učinkov na dobro počutje mater ali na plodnost samic, embriofetalne, peri- in postnatalne reproduktivne indekse.
No adverse events have been reported in the target species.
Ni poročil o škodljivih posledicah pri ciljnem rodu.
No adverse events were reported in the post marketing use of ImmunoGam for Immunoprophylaxis of Hepatitis B indication.
V obdobju trženja zdravila ImmunoGam za indikacijo imunoprofilaksa proti hepatitisu B ni bilo prijavljenih neželenih učinkov.
No adverse findings were observed in rat and rabbit embryofoetal development studies at doses up to at least 10 times the adult/children recommended dose and in rat fertility and peri- postnatal development studies at doses up to 10 times the adult/children recommended dose.
Neželenih izsledkov v študijah embrio-fetalnega razvoja pri podganah in kuncih pri odmerkih, ki so bili do vsaj 10-krat večji od priporočenega odmerka pri odraslih/otrocih ter študijah plodnosti in peri- ter postnatalnega razvoja pri podganah pri odmerkih, do 10-krat večjih kot je priporočeni odmerek pri odraslih/otrocih, niso opazili.
No adverse liver changes were seen in rats and monkeys following chronic administration of brivaracetam at 5- and 42- fold the clinical AUC exposure.
Pri podganah in opicah po kroničnem dajanju brivaracetama pri od 5- do 42-kratni klinični izpostavljenosti AUC niso opazili neželenih učinkov na jetra.
No adverse reaction was identified related to these LDL-C values.
Imunogenost/protitelesa proti zdravilu (ADA)
No adverse reactions except those mentioned in section 4.6 were observed after the administration of a 10-fold vaccine dose.
Po dajanju 10-kratnega odmerka cepiva ni bilo opaziti neželenih učinkov razen tistih, ki so navedeni v poglavju 4.6.
No adverse reactions except those mentioned in section 4.6 were observed after the administration of a double dose of vaccine.
Po dajanju dvojnega odmerka cepiva ni bilo opaziti nobenih drugih neželenih učinkov kot tistih, opisanih v poglavju 4.6.
No adverse reactions except those mentioned in section 4.6 were observed after the administration of a double dose of vaccine.
Po odmerjanju dvojnega odmerka cepiva ni bil opažen noben neželen učinek razen tistih, ki so omenjeni v poglavju 4.6.
No adverse reactions except those mentioned in section ‘Adverse Reactions’ were observed after the administration of a double-dose of vaccine.
Drugi učinki, razen tistih ki so navedeni v poglavju neželeni učinki, niso bili opaženi po dajanju dvojnega odmerka cepiva.
No adverse reactions except those mentioned in section ‘Adverse Reactions’ were observed after the administration of a double-dose of vaccine.
Drugi učinki, razen tistih, ki so navedeni v poglavju neželeni učinki, niso bili opaženi po dajanju dvojnega odmerka cepiva.
No adverse reactions except those mentioned in section “adverse reactions” were observed after the administration of a double dose to calves, lambs and piglets.
Po dajanju dvakratnega odmerka pri teletih, jagnjetih in pujskih niso bili opisani nobeni drugi neželeni učinki, razen omenjenih v poglavju Neželeni učinki.
No adverse reactions have been associated with these reports.
S tem prevelikim odmerjanjem niso bili povezani nobeni neželeni učinki.
No adverse reactions have been noted following an 8-fold overdose.
Po dajanju 8-kratnega prevelikega odmerka niso opazili nobenih neželenih učinkov.
No adverse reactions have been observed after the administration of a 10 fold overdose of the vaccine.
Priajanju 10-krat večjih odmerkov od priporočenega pri cepljenih živalih niso opazili neželenih učinkov.
No adverse reactions have been observed at up to 3-fold overdose in breeders.
Stranskih učinkov niso opazili pri do trikratnem odmerku pri vzrejnih živalih.
No adverse reactions have been observed at up to 5-fold overdose in layers and broilers (aged 21 days).
Stranskih učinkov niso opazili pri do petkratnem odmerku pri nesnicah in brojlerjih (starih 21 dni).
No adverse reactions have been observed at up to ten-fold overdose in pigs.
Stranskih učinkov niso opazili pri do desetkratnem odmerku pri prašičih.
No adverse reactions of memantine were noted on male and female fertility.
Neželenih učinkov v zvezi s plodnostjo pri moških ali ženskah niso opazili.
No adverse reactions other than already mentioned under point 4.6 can be expected, except for an increase of rectal temperature up to 2ºC. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.
Neželenih učinkov poleg že omenjenih v točki 4.6 ni pričakovati, razen zvišanja rektalne temperature za do 2ºC. Zvišanje rektalne temperature spontano izzveni v 24 urah brez zdravljenja.
No adverse reactions other than already mentioned under point “Adverse reactions” can be expected, except for an increase of rectal temperature up to 2ºC. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.
Neželenih učinkov poleg že omenjenih v točki 6 ni pričakovati, razen zvišanja rektalne temperature za do 2 ºC. Zvišanje rektalne temperature spontano izzveni v 24 urah brez zdravljenja.
No adverse reactions other than those described in section 4.6 have been observed following simultaneous subcutaneous administration of up to 10 times the recommended dose.
Po sočasnem subkutanem dajanju do 10-kratnega priporočenega odmerka niso opazili neželenih učinkov, razen tistih, opisanih v poglavju 4.6.
No adverse reactions other than those described in the section “Adverse reactions” have been observed following subcutaneous administration of up to 10 times the recommended dose.
Po subkutanem dajanju do 10-kratnega odmerka niso opazili nezaželenih učinkov, razen tistih, opisanih v poglavju 4.6..
No adverse reactions other than those mentioned in section 4.6 were observed after the administration of a double dose of vaccine.
Po uporabi dvojnega odmerka cepiva neželenih učinkov razen tistih, ki so navedeni v poglavju 4.6, ni bilo opaziti.
No adverse reactions other than those mentioned in section 4.6 were observed after the administration of a double-dose of the vaccine.
Po dajanju dvojnega odmerka cepiva niso opazili neželenih učinkov, razen tistih, navedenih v poglavju 4.6.
No adverse reactions other than those mentioned in section 4.6. were observed after the administration of an overdose of vaccine.
Po vnosu prevelikega odmerka niso zasledili drugačnih neželenih učinkov, kot so opisani v poglavju 4.6.
No adverse reactions other than those mentioned in section 6 have been observed.
Zasledili niso nikakršnih neželenih učinkov, ki bi se razlikovali od tistih, ki so našteti v poglavju 4.6.
No adverse reactions other than those mentioned in section 6 were observed after the administration of a double-dose of the vaccine.
Po dajanju dvojnega odmerka cepiva niso opazili neželenih učinkov, razen tistih, navedenih v poglavju 'Neželeni učinki'.
No adverse reactions that could be related to the veterinary medicinal product were observed in dogs with otitis externa under field conditions when administered as indicated in section 4.9.
V praksi pri psih z vnetjem sluhovoda niso opazili neželenih učinkov, ki bi lahko bili povezani s tem zdravilom, če so ga dajali po navodilih iz poglavja 4.9.
No adverse reactions that could be related to the veterinary medicinal product were observed in dogs with otitis externa under field conditions.
V praksi pri psih z vnetjem sluhovoda niso opazili neželenih učinkov, ki bi lahko bili povezani s tem zdravilom.
No adverse reactions were observed after an overdose administration (10 doses of lyophilisate and 2 doses of solvent) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Po dajanju prevelikega odmerka (10 odmerkov liofilizata in 2 odmerka topila) zdravila za uporabo v veterinarski medicini ni bilo opaziti neželenih učinkov, razen tistih, ki so omenjeni v poglavju 4.6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).
No adverse reactions were observed after an overdose administration (10 doses of lyophilisate and 2 doses of solvent) of the veterinary medicinal product other than those mentioned in section 6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Po dajanju prevelikega odmerka (10 odmerkov praška in 2 odmerka vehikla) zdravila za uporabo v veterinarski medicini ni bilo opaziti neželenih učinkov, razen tistih, ki so omenjeni v poglavju 4.6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).
No adverse reactions were observed after an overdose administration (2 doses) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Po aplikaciji prevelikega odmerka (2 odmerkov) zdravila za uporabo v veterinarski medicini ni bilo opažena neželenih učinkov, razen tistih, ki so omenjeni v poglavju 4.6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).